Literature DB >> 2119419

The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia.

N Hoogerbrugge1, M J Mol, J J Van Dormaal, C Rustemeijer, E Muls, A F Stalenhoef, J C Birkenhäger.   

Abstract

Forty patients with familial hypercholesterolaemia (FH) were treated with 40 mg pravastatin once daily. Pravastatin decreased serum total and low density lipoprotein cholesterol (LDL) after 8 weeks of treatment by 28% and 33%, respectively, while high density lipoprotein cholesterol increased by 8% and triglycerides decreased by 14%. In 30 patients LDL cholesterol had not decreased below 5.0 mmol l-1 after 8 weeks of treatment, and in these patients resins were added to pravastatin, resulting in an additional decrease in total and LDL cholesterol of 8% and 12%, respectively. A control group of 22 FH patients was treated with placebo for 10 weeks, after which time resins were added, and they induced a decrease in total and LDL-cholesterol of 17% and 22%, respectively. Our results over a 24-week treatment period indicate that 40 mg pravastatin is more effective than 3 packets of resins in lowering LDL cholesterol, whereas the combination is most effective of all and can be used safely.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2119419     DOI: 10.1111/j.1365-2796.1990.tb00229.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  6 in total

1.  Short- and long-term effects of lovastatin and pravastatin alone and in combination with cholestyramine on serum lipids, lipoproteins and apolipoproteins in primary hypercholesterolaemia.

Authors:  B G Jacob; W Möhrle; W O Richter; P Schwandt
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  HMG-CoA reductase inhibitor use in the aged. A review of clinical experience.

Authors:  C J Lintott; R S Scott
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923

Review 3.  Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.

Authors:  David Williams; John Feely
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Pravastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia.

Authors:  D McTavish; E M Sorkin
Journal:  Drugs       Date:  1991-07       Impact factor: 9.546

5.  Fluvastatin efficacy and tolerability in comparison and in combination with cholestyramine.

Authors:  E Hagen; H Istad; L Ose; E Bodd; H M Eriksen; V Selvig; J M Bard; J C Fruchart; M Borge; M C Wolf
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

6.  Bile Acid and Cholesterol Metabolism in Atherosclerotic Cardiovascular Disease and Therapy.

Authors:  John Y L Chiang; Jessica M Ferrell; Yue Wu; Shannon Boehme
Journal:  Cardiol Plus       Date:  2020-12-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.